IGLV5-37: A Potential Drug Target and Biomarker (G28783)

Target Name: IGLV5-37

NCBI ID: G28783

IGLV5-37

Other Name(s): IGLV537 | immunoglobulin lambda variable 5-37 | V4-1 | Immunoglobulin lambda variable 5-37

IGLV5-37: A Potential Drug Target and Biomarker

IGLV5-37 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the IMP-1 gene family, which encodes for insulin-like peptides. IGLV5-37 has been shown to play a role in various physiological processes in the body, including blood sugar control and inflammation.

Drug Target Potential

IGLV5-37 has been identified as a potential drug target due to its unique structure and the various functions that it is involved in. One of the key reasons for its potential as a drug target is its high degree of cross-talk with other proteins. IGLV5-37 has been shown to interact with a wide range of proteins, including those involved in signaling pathways that are involved in a variety of biological processes.

Additionally, IGLV5-37 has been shown to play a role in the regulation of various cellular processes, including cell signaling, angiogenesis, and inflammation. Its involvement in these processes makes it an attractive target for drugs that are designed to modulate these processes.

Biomarker Potential

IGLV5-37 has also been identified as a potential biomarker for a variety of diseases. For example, IGLV5-37 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism, which are important factors in the development and progression of type 2 diabetes. Additionally, IGLV5-37 has been shown to be involved in the regulation of inflammation, which is a key factor in the development of various inflammatory diseases.

Conclusion

In conclusion, IGLV5-37 is a protein that has broad potential as a drug target and biomarker. Its unique structure and the various functions that it is involved in make it an attractive target for drugs that are designed to modulate these processes. Further research is needed to fully understand the role of IGLV5-37 in various biological processes and to determine its potential as a drug target and biomarker.

Protein Name: Immunoglobulin Lambda Variable 5-37

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV5-37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV5-37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets